jnj 10229570
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01326780)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj 10229570
- jnj 10229570
- jnj 10229570-aaa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01492647 | Phase 1 | Aug 1, 2011 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01494714 | Phase 1 | Aug 1, 2011 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01326780 | Phase 2 | Mar 1, 2011 | Bausch Health Companies |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 1 | 2011 |
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2011 |
| Bausch Health Companies | For profit | 1 | 1 | 1 | 2011 |
3 organizations
Page 1 / 1